wAMD · Ophthalmology · 4 drugs · 2 indications
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|---|---|---|---|---|
| ABBV-RGX-314 | ABBV | AAV gene therapy (anti-VEGF) | Gene therapy | Intravitreal | PHASE3 |
| Lucentis | ROG.SW, NVS | VEGF antagonist | Antibody fragment | Intravitreal | APPROVED |
| EYLEA | REGN | VEGF trap (fusion protein) | Fusion protein | Intravitreal | APPROVED |
| EYLEA HD | REGN | VEGF trap (fusion protein) | Fusion protein | Intravitreal | APPROVED |